Novartis, Novartis [clinicaltrials_resource:6d8c029072ce4da24caccc964c0f4d1f]
Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A302 [clinicaltrials:NCT00149864]clinicaltrials:NCT00149890Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A301 [clinicaltrials:NCT00149929]Safety and Efficacy of Converting Maintenance Kidney and Liver Transplant Recipients With Abnormal Glucose Metabolism From Tacrolimus to Cyclosporine Micro-emulsion [clinicaltrials:NCT00150085]Study of Safety and Efficacy of a Basiliximab, Mycophenolate Mofetil, Cyclosporine Microemulsion and Prednisone Combination Treatment Regimen in Pediatric Renal Allograft Recipients [clinicaltrials:NCT00228020]Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients [clinicaltrials:NCT00238953]Extension Study on the Efficacy and Safety of Enteric-coated Mycophenolate Sodium Administered in de Novo Kidney Transplant Patients [clinicaltrials:NCT00239018]Extension Study on the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant Recipients [clinicaltrials:NCT00239070]Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients [clinicaltrials:NCT00239083]clinicaltrials:NCT00251004clinicaltrials:NCT00284934An Open, Randomized Pilot Study to Evaluate the Use of Basiliximab With an Optimized Cyclosporine Dosing on Renal Function in "de Novo" Liver Transplantation. [clinicaltrials:NCT00343226]clinicaltrials:NCT00376259Efficacy and Safety of the Pediatric Formulation of Artemether- Lumefantrine in Children With Uncomplicated P. Falciparum Malaria. [clinicaltrials:NCT00386763]Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension [clinicaltrials:NCT00387517]clinicaltrials:NCT00419926clinicaltrials:NCT00444106Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment [clinicaltrials:NCT00567047]Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired Patients [clinicaltrials:NCT00572650]Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Rheumatoid Arthritis With Ongoing Treatment With Methotrexate [clinicaltrials:NCT00619905]Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects [clinicaltrials:NCT00620230]Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma [clinicaltrials:NCT00624702]clinicaltrials:NCT00624832Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes [clinicaltrials:NCT00633997]clinicaltrials:NCT00654875clinicaltrials:NCT00705575clinicaltrials:NCT00706134
responsible party [clinicaltrials_vocabulary:responsible-party]
Novartis, Novartis [clinicaltrials_resource:6d8c029072ce4da24caccc964c0f4d1f]
Bio2RDF identifier
6d8c029072ce4da24caccc964c0f4d1f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:6d8c029072ce4da24caccc964c0f4d1f
name title [clinicaltrials_vocabulary:name-title]
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:6d8c029072ce4da24caccc964c0f4d1f
title
Novartis, Novartis
@en
type
label
Novartis, Novartis [clinicaltrials_resource:6d8c029072ce4da24caccc964c0f4d1f]
@en